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Abstract
Background: Epigenetic inactivation of tumor suppressor genes (TSG) by promoter CpG island hypermethylation is
a hallmark of cancer. To assay its extent in human lymphoma, methylation of 24 TSG was analyzed in lymphoma-
derived cell lines as well as in patient samples.
Methods: We screened for TSG methylation using methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) in 40 lymphoma-derived cell lines representing anaplastic large cell lymphoma, Burkitt
lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Hodgkin lymphoma and mantle
cell lymphoma (MCL) as well as in 50 primary lymphoma samples. The methylation status of differentially
methylated CD44 was verified by methylation-specific PCR and bisulfite sequencing. Gene expression of CD44 and
its reactivation by DNA demethylation was determined by quantitative real-time PCR and on the protein level by
flow cytometry. Induction of apoptosis by anti-CD44 antibody was analyzed by annexin-V/PI staining and flow
cytometry.
Results: On average 8 ± 2.8 of 24 TSG were methylated per lymphoma cell line and 2.4 ± 2 of 24 TSG in primary
lymphomas, whereas 0/24 TSG were methylated in tonsils and blood mononuclear cells from healthy donors.
Notably, we identified that CD44 was hypermethylated and transcriptionally silenced in all BL and most FL and
DLBCL cell lines, but was usually unmethylated and expressed in MCL cell lines. Concordant results were obtained
from primary lymphoma material: CD44 was not methylated in MCL patients (0/11) whereas CD44 was frequently
hypermethylated in BL patients (18/29). In cell lines with CD44 hypermethylation, expression was re-inducible at
mRNA and protein levels by treatment with the DNA demethylating agent 5-Aza-2’-deoxycytidine, confirming
epigenetic regulation of CD44. CD44 ligation assays with a monoclonal anti-CD44 antibody showed that CD44 can
mediate apoptosis in CD44
+ lymphoma cells. CD44 hypermethylated, CD44
- lymphoma cell lines were consistently
resistant towards anti-CD44 induced apoptosis.
Conclusion: Our data show that CD44 is epigenetically regulated in lymphoma and undergoes de novo
methylation in distinct lymphoma subtypes like BL. Thus CD44 may be a promising new epigenetic marker for
diagnosis and a potential therapeutic target for the treatment of specific lymphoma subtypes.
Background
Cancer cells display multiple defects in cellular pathways
that govern normal cellular proliferation and homeosta-
sis. During their development cancer cells acquire a set
of functional capabilities for malignant growth, usually
including self-sufficiency in growth signals, insensitivity
to growth-inhibitory signals, evasion from apoptosis,
limitless replicative potential, sustained angiogenesis,
and tissue invasion and metastasis [1]. These essential
alterations in cell physiology are, amongst others,
achieved by the constitutive activation of oncogenes and
the loss of tumor suppressor gene (TSG) function. Both,
genetic and epigenetic mechanisms contribute to the
inactivation of TSG. Genetic alterations often include
deletions and loss-of-function mutations. Furthermore,
TSG may become epigenetically silenced by hyper-
methylation of CpG islands located in their promoter
regions, which are usually unmethylated in normal
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is catalyzed by DNA methyltransferases [4]. DNA
methylation interferes with binding of transcription fac-
tors and, additionally, methylated CpG are bound by
methyl-CpG binding proteins that induce the formation
of inactive chromatin by interacting with histone deace-
tylases, resulting in transcriptional repression [2,5]. Epi-
genetic silencing of TSG is potentially reversible. Thus,
hypermethylated TSG promoters represent therapeutic
targets for DNA demethylating agents like 5-Aza-2’-
deoxycytidine (Aza, Decitabine), as already demonstrated
in clinical trials [6].
TSG hypermethylation in cancer cells has strong specifi-
city with respect to the tissue of origin and tumor-type-
specific methylation patterns have been reported for pri-
mary human tumors and cancer cell lines [7-11]. Several
studies showed differential DNA methylation patterns and
discovered subtype-specific epigenetic markers in diverse
lymphoid malignancies [12-15]. Furthermore, hypermethy-
lation of certain TSG can be correlated with prognosis
[16-18]. Yet, functional and genetic studies are necessary
for the determination of lymphomagenesis-relevant hyper-
methylation events.
We aimed to analyze TSG methylation patterns in
a broad spectrum of Hodgkin lymphoma-(HL) and
non-Hodgkin lymphoma-(NHL) derived cell lines and
primary samples to identify novel characteristic methy-
lation patterns of TSG. Besides the discovery of gener-
ally hypermethylated TSG, we identified TSG with
subtype-specific methylation patterns. One of these
novel candidates was CD44, formerly described as lym-
phocyte homing receptor [19]. CD44 hypermethylation
resulting in gene silencing has already been reported for
other cancer types like prostate cancer and neuroblas-
toma [20-22]. Recently, CD44 has been shown to be a
novel translocation partner of IGH in mature B-cell
malignancies resulting in overexpression of CD44 lack-
ing exon 1 [23].
We show here, that CD44 was frequently hypermethy-
lated and transcriptionally silenced in anaplastic large
cell lymphoma (ALCL), Burkitt lymphoma (BL), diffuse
large B-cell lymphoma (DLBCL) and follicular lym-
phoma (FL) cell lines, whereas it was unmethylated and
expressed in most HL and mantle cell lymphoma
(MCL) cell lines. Importantly, this methylation and
expression pattern resembled that of primary lympho-
mas. Experiments with a DNA demethylating agent veri-
fied epigenetic regulation of CD44.F u r t h e r m o r e ,CD44
hypermethylated cell lines were resistant towards anti-
CD44 induced apoptosis. This supports a tumor sup-
pressor role for CD44 in lymphoma and highlights
CD44 as an interesting new potential epigenetic marker
and a valuable target for epigenetic therapy in distinct
lymphoma subtypes.
Methods
Human cell lines
Cell lines were either resourced from the DSMZ cell
repository (Braunschweig, Germany) or were gener-
o u s l yp r o v i d e db yo r i g i n a li n v estigators. Detailed refer-
ences and cultivation protocols have been described
previously [24].
Samples and patients
DNA was extracted from tumor containing tissues diag-
nosed or suspicious for Burkitt lymphoma/leukemia, in
which chromosome analysis revealed the presence for a
Burkitt translocation t(8;14) or variants, and from frozen
sections of DLBCL and MCL from untreated patients
using the DNeasy Mini Kit (Qiagen, Hilden, Germany).
The study on BL material was performed according to
the protocols of the network “Molecular Mechanisms in
Malignant Lymphoma” for which approval by the Ethics
Committee of the Medical Faculty of the Christian-
Albrechts-University Kiel was obtained. The study on
DLBCL and MCL material was approved by the local
Ethics Committee of the Medical Faculty of the Univer-
sity of Würzburg.
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
The MS-MLPA assay (ME001B; MRC-Holland, Amster-
dam, Netherlands) simultaneously detects copy number
changes and CpG methylation of the promoter regions
of 24 different TSG. This semi-quantitative technique is
based on digestion of DNA with the methylation-sensi-
tive restriction enzyme HhaI (Fermentas, St. Leon-Rot,
Germany) and a subsequent multiplex PCR followed by
fragment analysis via capillary electrophoresis [25]. MS-
MLPA data were analyzed using a Microsoft Excel
spreadsheet from the National Genetics Reference
Laboratory designed specifically for the ME001B assay
http://www.ngrl.org.uk/Manchester/projects/informatics/
mlpa. Levels of methylation were calculated by compar-
ing relative peak areas of the HhaI digested ligation pro-
ducts with the corresponding ligation products from
undigested samples. Peak areas were normalized relative
to neighboring control ligation products prior to com-
parison. Samples with a methylation level > 10% were
regarded as methylated.
Aza treatment for demethylation of DNA
5-Aza-2’-deoxycytidine (Sigma-Aldrich, Taufkirchen,
Germany) dissolved in DMSO was used to verify the
effect of promoter methylation on TSG expression. Cells
were seeded at a density of 5 × 10
5/ml, Aza was added
at a final concentration of 5 μM. Vehicle control cells
were treated with 0.05% DMSO. After 2 days, half of the
medium was replenished with medium with/without
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prepare RNA or used for CD44 detection by flow
cytometry.
RNA isolation and quantitative real-time PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen)
including DNase digestion. Reverse transcription was
performed with SuperScript II reverse transcriptase Kit
(Invitrogen, Karlsruhe, Germany). qRT-PCR for gene
expression analysis was performed on an Applied Bio-
systems 7500 SDS real-time PCR system (Darmstadt,
Germany). Expression of RPS9 as endogenous control
and of CD44 and CD44v6 was assessed using SYTO-82
(Molecular Probes, Leiden, Netherlands) as fluorescent
dye and ImmoMix (Bioline, Luckenwalde, Germany) as
PCR master mix. Primers were the following: CD44 fwd
5’-CAA TAG CAC CTT GCC CAC AAT-3’, CD44 rev
5’-AAT CAC CAC GTG CCC TTC TAT GG-3’,
CD44v6 fwd 5’-GAT CAC CGA CAG CAC AGA CA-3’,
CD44v6 rev 5’-CCA TCT GTT GCC AAA CCA CTG-
3’, RPS9 fwd 5’-GGG AAG CGG AGC CAA CAT G-3’,
RPS9 rev 5’-GTT TGT TCC GGA GCC CAT ACT-3’.
Relative gene expression levels were calculated using the
ΔΔCt-method.
Bisulfite conversion and methylation-specific PCR (MSP)
Bisulfite conversion of DNA was performed as described
by the supplier (EpiTect Bisulfite Kit, Qiagen). For
methylation analysis of the CD44 (ENSEMBL ID
ENSG00000026508) exon 1 region, including the regula-
tory promoter region described by Shtivelman and
Bishop [26], we performed nested PCR with first-round
primers CD44 BSP fwd 5’-GGT TGA ATT TAA
TGG TGT AAG G-3’ and CD44 BSP rev 5’-ACA ACT
CAC TTA ACT CCA ATC C-3’ amplifying bisulfite-
converted DNA independently of the CD44 methylation
status (bisulfite-specific PCR, BSP), while second-round
primers for M-PCR CD44 M_fwd 5’-TCG TTG AGT
TTG GCG TAG ATC-3’,C D 4 4M _ r e v5 ’-ACT ACC
G C CG A AT C CG C G - 3 ’ and for U-PCR CD44 U_fwd
5’-GTG TTG TTG AGT TTG GTG TAG ATT-3’,
CD44 U_rev 5’-CAA AAA AAC TAC CAC CAA ATC
CAC A-3’ specifically recognized the methylated or
unmethylated versions of the region. PCR products of
the initial BSP were diluted 1:100 for subsequent MSP.
Epitect PCR Control DNA (Qiagen) was used as control
for methylated and unmethylated templates.
Bisulfite sequencing
For bisulfite sequencing of the CD44 exon 1 region,
CD44-BSP products obtained with primers CD44 BSP
fwd and CD44 BSP rev (sequences see previous section),
were purified and subcloned into the pGEM-Teasy plas-
mid vector (Promega, Mannheim, Germany). Plasmid
DNA from at least eight insert-positive clones for each
sample was isolated using QIAprep Spin Miniprep Kit
(Qiagen) and subjected to automated sequencing.
Sequences were evaluated using BiQ Analyzer http://
biq-analyzer.bioinf.mpi-sb.mpg.de [27] and had to con-
form to at least 90% bisulfite conversion rate. Identical
clones were excluded from the analysis as well.
Analysis of CD44 protein expression by flow cytometry
For detection of CD44 on the cell surface, cells were
washed and incubated with mouse anti-human CD44
mAB (clone G44-26, BD Biosciences, Heidelberg, Ger-
many) or with the isotope-matched control mouse
immunoglobulin (BD Biosciences) for 30 min at 4°C.
Subsequently, cells were treated with FITC conjugated
anti-mouse secondary antibody (Biozol, Eching, Ger-
many) and Propidium Iodide (PI) (Sigma-Aldrich).
Labeled cells were analyzed on a FACSCalibur (BD Bios-
ciences) using CellQuest Pro software.
CD44 splice variant analysis
For the analysis of CD44 splice variants, reverse tran-
scriptase PCR was performed using CD44 primers flank-
ing all variant exons: CD44 exon 5 s fwd 5’-CAG ACA
GAA TCC CTG CTA CCA-3’,C D 4 4E x o n7sr e v
5’-GTC CTT ATA GGA CCA GAG GTT G-3’.T h e
PCR reaction mixture was cycled for 30 s at 94°C, 30 s
at 62°C, and 1 min at 72°C for 40 cycles. The PCR pro-
duct of CD44 s corresponds to 142 bp. For sequencing
of unknown splice variants, PCR products were sliced
from agarose gel, purified with QIAquick Gel Extraction
K i t( Q i a g e n )a n ds u b c l o n e di n t ot h ep G E M - T e a s yp l a s -
mid vector (Promega). Plasmid DNA was isolated using
QIAprep Spin Miniprep Kit (Qiagen) and subjected to
automated sequencing.
CD44 ligation and annexin-V staining
Cells were seeded at 10
6/ml in 96-well tissue culture plates
and cultured in the presence of anti-CD44 mAb (clone
G44-26, BD Biosciences) or the isotope-matched control
mouse immunoglobulin (BD Biosciences) at a concentra-
tion of 5 μg/ml or 20 μg/ml for 24 h. Cells were then pro-
cessed for apoptosis studies via annexin-V staining using
the TACS Annexin-V-FITC Kit (R&D Systems, Wiesba-
den, Germany) according to the manufacturer’si n s t r u c -
tions. Cells were analyzed by flow cytometry on a
FACSCalibur (BD Biosciences) using CellQuest Pro
software.
Results and Discussion
Screening for tumor suppressor gene methylation with
MS-MLPA
Besides gene deletions, TSG are a frequent subject of
promoter hypermethylation in tumor cells. Both types of
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quantify epigenetic and genetic changes of 24 TSG, we
used the semi-quantitative MS-MLPA assay. We
screened a panel of 40 lymphoma cell lines (Figure 1)
representing HL and five distinct subtypes of NHL
(ALCL, BL, DLBCL, FL and MCL) and 50 primary lym-
phoma samples from BL, DLBCL and MCL patients
(Additional File 1) to identify TSG methylation patterns
and TSG deletions. As expected, control DNA of tonsils
and peripheral blood mononuclear cells (PBMC) from
three healthy donors showed no methylation or deletion
of any TSG (Figure 1).
On average 8 ± 2.8 of 24 TSG were methylated per
lymphoma cell line. TSG deletions were less frequent
with an average of 2.4 ± 1.5 per cell line. The loss of
one allele and methylation of the second one could be
observed frequently in lymphoma cell lines for RARB
(retinoic acid receptor beta)a n dt oal e s s e re x t e n tf o r
TIMP3 (tissue inhibitor of metalloproteinase 3), IGSF4
(immunoglobulin superfamily member 4,a l i a sCADM1)
and ESR1 (estrogen receptor 1) (Figure 1). The examina-
tion of primary material from 29 BL, 10 DLBCL and 11
MCL patients with MS-MLPA showed that the average
number of methylated TSG in primary material was
Figure 1 Methylation status and deletions of TSG in lymphoma cell lines. MS-MLPA results of 40 lymphoma cell lines show the methylation
status and copy number of 24 TSG. As control, DNA samples from tonsils and PBMC of three healthy donors were analyzed. In each lymphoma
subgroup cell lines are arranged alphabetically. TSG are sorted from left to right according to frequency of methylation and/or deletion.
According to the incidences of methylated and/or deleted TSG in cell lines, TSG can be divided in 3 groups: group A (methylated and/or
deleted in ≤ 10% of cell lines), group B (methylated and/or deleted in 10 to 89% of cell lines) and group C (methylated and/or deleted in
≥ 90%). yellow = TSG unmethylated and not deleted; green = TSG methylated and/or deleted; del = deleted; o. del = only deleted, not
methylated.
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File 1). The higher level of CpG island hypermethylation
identified in cell lines in comparison to the primary
tumors has also been reported by others [28]. However,
although cancer cell lines have an increased rate of
hypermethylation of certain CpG islands, they retain the
specific CpG island hypermethylation profile of each
tumor cell [9,29]. Consistently, the most frequently
methylated TSG were the same in cell lines and primary
samples: DAPK1 (death-associated protein kinase 1),
RARB, CDH13 (cadherin 13), IGSF4, TIMP3, ESR1 and
CD44.
The presence of generally and differentially methylated
TSG among the lymphoma subtypes analyzed is in line
with previous reports describing the existence of genes
commonly hypermethylated in various tumors and
genes being epigenetically silenced in a subtype-specific
manner [7,15]. Some of the observed TSG methylation
patterns in lymphoma cell lines (e.g. for DAPK1,
RASSF1) support previous methylation analyses per-
formed on primary lymphoma patient material [30-33].
In addition, the MS-MLPA screening in lymphoma cell
lines and primary samples led to the identification of
novel TSG methylation profiles for RARB, TIMP3,
CDH13, IGSF4 and ESR1 which were frequently methy-
lated in lymphoma (Figure 1, Additional File 1).
From our point of view CD44 showed the most inter-
esting and hitherto unknown methylation pattern: it was
methylated in all BL cell lines (7/7) but not methylated
in most of the MCL cell lines (1/7) (Figure 1). Further-
more, CD44 methylation was detected in 9/29 BL
patient samples but not in any of the MCL patients (0/
11) (Additional File 1). To our knowledge there are no
reports on the potentially epigenetic regulation of CD44
in lymphoma cells.
Verification of differential CD44 methylation in lymphoma
The MS-MLPA assay result is based on the methylation
status of only one single CpG site in the context of an
HhaI restriction site in the promoter region of a gene,
rendering it suitable as a screening-method [25]. To
assess the significance of the CD44 methylation status
obtained by MS-MLPA, we analyzed CD44 methylation
with additional independent techniques: methylation-
specific PCR (MSP) and bisulfite sequencing (Figures 2
and 3). After bisulfite conversion of DNA we deter-
mined the methylation status of CD44 with MSP in the
lymphoma cell lines (Figure 2A) and primary samples
(Figure 2B). According to MSP CD44 was methylated in
all (7/7) BL cell lines, frequently methylated in ALCL
(4/5), FL (4/6) and DLBCL (6/8) cell lines, and to a les-
ser extent methylated in HL (3/7) and MCL (2/7) cell
lines, which matched the MS-MLPA results (Figure 2A).
In accordance with the CD44 methylation pattern
observed in cell lines, CD44 was frequently methylated
in BL patients (18/29) but not methylated in MCL
patients (0/11) (Figure 2B). In contrast only one DLBCL
patient (1/10) showed CD44 methylation (Figure 2B),
thus CD44 methylation occurred less frequently in
DLBCL patients than in DLBCL cell lines. Overall, the
results of MSP and MS-MLPA showed good concor-
dance in cell lines (87.5%) and primary samples (74%) as
well. In particular cases the different results of MS-
MLPA and MSP might be the consequence of distinct
CpG sites analyzed. Additionally, MSP is more sensitive
than MS-MLPA.
Therefore, the methylation status of CD44 in lym-
phoma cell lines and primary samples was finally veri-
fied by bisulfite sequencing of the CpG island spanning
exon 1 of CD44. Sequencing confirmed dense CpG
methylation of CD44 in the BL cell line EB-1, which
was CD44 hypermethylated according to MS-MLPA and
MSP (Figure 3). In line with MS-MLPA and MSP
results, the MCL cell line REC-1 showed no hyper-
methylation of the exon 1 region of CD44 (Figure 3).
Also in primary samples bisulfite sequencing verified the
MSP results: BL patient BL23 harbored clones with
dense CpG methylation in the exon 1 region of CD44,
whereas MCL patient MCL2 was not methylated at
nearly all CpG sites analyzed. DLBCL patient DLBCL1
showed only partial methylation of the CpG sites next
to the ATG codon. Furthermore, tonsil DNA of a
healthy donor had a completely unmethylated CD44
exon 1 region (Figure 3). Thus, CD44 might in fact
represent a TSG undergoing de novo methylation in dis-
tinct lymphoma subtypes like BL.
CD44: a novel epigenetically regulated TSG in lymphoma
Methylation of TSG has biological relevance if hyper-
methylation of the promoter region inhibits gene expres-
sion. To evaluate the correlation between methylation of
the CD44 exon 1 region and CD44 transcription we per-
formed quantitative real-time PCR (qRT-PCR) with
cDNA from lymphoma cell lines. CD44 was expressed in
all (7/7) MCL, most (5/7) HL and some (3/5) ALCL cell
lines, but rarely transcribed in BL, FL and DLBCL cell
lines (Figure 4A). In the majority of the lymphoma
cell lines (80%), CD44 gene expression was inversely
correlated with CD44 hypermethylation as highlighted by
the color of the columns (Figure 4A). This is a remark-
able correlation and suggests that CD44 is indeed regu-
lated by DNA methylation in lymphoma cells.
Next, we investigated whether CD44 hypermethylation
was also inversely correlated with CD44 protein expres-
sion. Cell surface CD44 protein expression was analyzed
by flow cytometry with anti-CD44 (G44-26) monoclonal
antibody (mAb) directed against epitope 1, recognizing
all forms of CD44 [34]. CD44 protein was expressed on
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mRNA and predominantly unmethylated in the CD44
exon 1 region, especially in MCL and HL cell lines. Cell
lines with CD44 hypermethylation were negative for
CD44 mRNA and CD44 protein (Table 1, Figure 4B).
Thus, CD44 hypermethylation was inversely correlated
with gene transcription and protein expression in lym-
phoma cell lines.
To test whether CD44 expression is epigenetically
regulated via promoter met h y l a t i o ni nl y m p h o m a ,w e
treated cell lines with Aza, leading to DNA demethyla-
tion. The results confirmed that hypermethylation of
CD44 was responsible for gene silencing since DNA
demethylation resulted in reactivation of CD44 tran-
scription in CD44 hypermethylated cell lines, but not in
CD44 unmethylated cell lines as determined by qRT-
P C R( F i g u r e5 A ,T a b l e1 ) .F u r t h e r m o r e ,A z at r e a t m e n t
resulted in induction of CD44 protein expression as
shown for cell lines KARPAS-299 (ALCL), EB-1 (BL)
and RAJI (BL) by flow cytometry (Figure 5B). The effect
of Aza on methylated CD44 seemed to be direct since
two cell lines (DOGUM and WSU-DLCL2) which were
negative for CD44 despite being unmethylated, remained
CD44 negative after Aza treatment (Table 1). However,
these results show that DNA methylation is not the only
reason for CD44 silencing and other suppressive
mechanisms appear to play a role in DOGUM and
WSU-DLCL2. It has been reported that BCL-6 and p53
are repressors of CD44 [35,36]. In breast cancer CD44
c a nb es u p p r e s s e db ym i R - 3 7 3a n dm i R - 5 2 0 c[ 3 7 ] .
Alternatively, essential transcriptional activators might
be missing in the CD44
- and CD44 unmethylated cell
lines. In accordance with this view, the CD44 promoter
is reportedly stimulated by growth factors, particularly
by the Ras-Erk signaling pathway [38]. Interesting in
this context is also that hypermethylated CD44 could be
reactivated not only by Aza but also by cAMP in an
ATRA-resistant acute promyelocytic leukemia cell line
Figure 2 Methylation status of CD44 in 40 lymphoma cell lines and 50 patient samples according to MSP. CD44 methylation in
lymphoma cell lines (A) and material from BL, DLBCL and MCL patients (B) was analyzed by MSP after bisulfite conversion of the DNA. CD44
MSP agarose gels of M-and U-PCR are shown. The CD44 methylation status as determined by MS-MLPA is indicated underneath: M = sample
methylated, U = sample unmethylated.
Eberth et al. BMC Cancer 2010, 10:517
http://www.biomedcentral.com/1471-2407/10/517
Page 6 of 14[39]. Thus DNA methylation is one important but not
exclusive mechanism regulating the expression of CD44.
Significantly, CD44 protein expression data from pri-
mary lymphoid material reported by others resemble
the CD44 expression pattern, which we observed in
lymphoma cell lines (Table 2). The standard CD44 iso-
form CD44s, skipping all variant exons, is mainly
expressed in hematopoietic cells and shows high expres-
sion in normal lymphoid tissue [40-42]. Already hema-
topoietic progenitor cells display positivity for CD44
[43]. In line with this, we identified no CD44 methyla-
tion in PBMC and tonsils of healthy donors thus
enabling transcription of CD44 in these cells (Figures 1
and 3). Thus, lymphomas with an unmethylated CD44
regulatory region and expressing CD44s reflect their
normal lymphocytic counterparts. MCL patient samples
are characteristically positiv ef o rC D 4 4 s[ 4 4 ] .T h i si si n
agreement with our data on MCL cell lines, showing
CD44 expression and an unmethylated CD44 promoter
(Table 2). Moreover, we detected no CD44 hypermethy-
lation in MCL patients (Figure 2B, Table 2). Lymphoma
cells of HL and ALCL patients have been described to
be often CD44 positive [45,46]. Consistent with these
data, HL, and to a lesser extent ALCL cell lines
expressed CD44 and had an unmethylated CD44 exon 1
region (Table 2). CD44 positive and negative cases have
been reported for DLBCL patients and it was shown
that CD44s expression is inversely correlated with clini-
cal disease stage [47]. However, the majority of DLBCL
cell lines did not express CD44 due to promoter hyper-
methylation (Table 2). In NHL patients with BL or
nodal FL CD44 is typically absent [45,48]. In accordance
with these reports, CD44 was not expressed and hyper-
methylated in all BL and most of the FL cell lines
(Table 2). Furthermore, we identified frequent hyper-
methylation of CD44 in BL patients (Figure 2B, Table
2), implying that DNA methylation is the reason for
CD44 silencing also in primary BL.
In conclusion, we propose that CD44 expression is
regulated by DNA methylation not only in lymphoma
cell lines, but also in the primary tumors. And we sup-
pose that the loss of CD44 mRNA and protein expres-
sion in distinct lymphoma subtypes is the consequence
of CD44 de novo methylation.
CD44 splice variant analysis
Depending on the cell type and the expression of CD44
splice variants CD44 proteins can have both oncogenic
Figure 3 Bisulfite sequencing of CD44 exon 1 region. The CpG island of CD44 is located between-638 and +496 relative to the ATG codon,
thereby spanning the whole exon 1. The CD44 exon 1 region (682 bp, 53 CpG sites) was sequenced after bisulfite conversion of DNA from cell
line EB-1 (BL) and cell line REC-1 (MCL) as well as from patient samples BL23 (BL), DLBCL1 (DLBCL) and MCL2 (MCL) and tonsil DNA from a
healthy donor. Each line depicts a sequenced clone representing the methylation status of an individual allele. CpGs are represented as open
dots (if unmethylated) or filled dots (if methylated). In BL cell line EB-1 and in the BL patient clones with dense CpG methylation were detected,
the DLBCL patient showed partial CpG methylation next to the ATG codon. In contrast no methylation of these sites was detectable in the MCL
cell line REC-1, the MCL patient and normal tonsil DNA. Bisulfite sequencing confirmed results of CD44 methylation status detected with MS-
MLPA and MSP. Note that CpG sites analyzed by the MS-MLPA probe (green) and MSP primers (red) are not identical.
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gical malignancies expression of CD44 variants is prog-
nostically significant. Notably, expression of the variant
isoform CD44v6 is associated with shorter overall survi-
val in patients with aggressive NHL [42]. Therefore, we
analyzed expression of CD44v6 in CD44
+ lymphoma cell
lines with qRT-PCR. However, none of the 15 analyzed
cell lines expressed the metastases-associated CD44v6
isoform (data not shown). Since we could not exclude
the expression of any other variant isoform from these
data alone, we investigated CD44 transcripts obtained
by RT-PCR with primers flanking the variant exons of
CD44 (Additional File 2). All CD44
+ lymphoma cell
lines and PBMC had the CD44s transcript. Sequencing
of the other PCR product obtained revealed that
CD44v10 was expressed in most of the CD44
+ cell lines
and PBMC, but to a significantly lesser extent than the
standard isoform CD44s (Additional File 2). Interest-
ingly, expression of CD44v10 has been reported for
Hodgkin and Reed-Sternberg cells in nodular sclerosis
Figure 4 Correlation between CD44 methylation and gene silencing. (A) Transcript levels of CD44 were analyzed by qRT-PCR in 40
lymphoma cell lines of the different lymphoma subtypes. RPS9 expression was used as endogenous control and cell line L-82 was used for
normalization. CD44 was primarily expressed in HL and MCL cell lines. Note the strong correlation between CD44 methylation (green columns)
and transcriptional silencing as well as CD44 non-methylation (yellow columns) and CD44 expression. The methylation status is shown according
to MS-MLPA analysis. (B) CD44 protein expression was analyzed in the CD44 methylated and mRNA-negative cell line SC-1 (FL) and in the CD44
unmethylated, mRNA-positive cell line REC-1 (MCL) by flow cytometry. In accordance with mRNA expression, only cell line REC-1 was positive for
CD44 protein. CD44 stained cells (filled histogram) and isotope control labeled cells (open histogram) are shown.
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prognosis [49]. However, CD44v10 mRNA is also pre-
sent in CD34
+ progenitor cells and normal peripheral
blood lymphocytes [50].
In conclusion, the CD44
+ lymphoma cell lines
expressed mainly CD44s, which as major splice variant
of normal lymphoid tissue is believed to exert tumor
suppressor functions.
CD44 hypermethylated lymphoma are resistant towards
anti-CD44 induced apoptosis
Uncontrolled activation of oncogenes and the loss of TSG
can promote sustained cell proliferation and tumorigen-
esis. Therefore, we decided to investigate whether the loss
of CD44 by DNA hypermethylation in certain NHL sub-
types might have functional consequences. CD44 activa-
tion by its natural ligand hyaluronic acid (HA) as well as
by appropriate anti-CD44 mAbs stimulates multiple cell
type-dependent CD44-associated functions, including pro-
liferation, differentiation, migration, contact inhibition,
and apoptosis [51]. In acute myeloid leukemia cell lines,
ligation of cell surface CD44 with an anti-CD44 mAb can
inhibit proliferation and induce apoptosis [52,53]. There-
fore, CD44
+ and CD44
- lymphoma cell lines were
cultivated for 24 h in the presence of an anti-CD44 mAb
(G44-26) or of a matched isotope control antibody and
were subsequently analyzed for induction of apoptosis via
annexin-V/PI staining (Figure 6). CD44 ligation led to a
considerable increase of early (annexin-V
+/PI
-) apoptotic
cells in the CD44
+ cell line REC-1 (MCL), whereas the
CD44
- cell line EB-1 (BL) was unaffected (Figure 6A).
Thus, the anti-CD44 mAb triggered apoptosis in CD44
+
and CD44 unmethylated cell lines (REC-1 and KM-H2),
whereas CD44
- lymphoma cell lines, which are CD44
hypermethylated, showed no response (Figure 6B). This
supports a tumor suppressor function for CD44 in lym-
phoma. Since resistance towards apoptosis is a hallmark of
most types of cancer, loss of CD44 due to de novo CpG
island hypermethylation in certain lymphoma subtypes,
especially observed in BL cell lines and patients may prove
advantageous for the tumor cell and promote lymphoma-
genesis. Accordingly, it has been reported for prostate can-
cer that hypermethylation of the CD44 promoter is
associated with the downregulation of CD44 expression
during metastic progression [21].
The fact that CD44
+ HL and MCL cell lines were sen-
sitive to anti-CD44 induced apoptosis may allow for
new therapeutic strategies by targeting cell surface
Table 1 CD44 methylation status, mRNA and protein expression in lymphoma cell lines
subtype cell line MS-MLPA MSP CD44 mRNA Aza induction of CD44 mRNA CD44 protein
HL KM-H2 M M/U positive - positive
L-428 M U positive n.d. positive
L-1236 U U positive n.d. n.d.
SUP-HD1 U U positive n.d. positive
ALCL DEL U M/U positive n.d. positive
KARPAS-299 M M/U negative +++ negative
BL CA-46 M M negative +++ negative
DAUDI M M/U negative + n.d.
EB-1 M M negative ++ negative
RAJI M M negative +++ negative
FL DOGUM U U negative - n.d.
DOHH-2 M M/U positive - n.d.
SC-1 M M/U negative +++ negative
WSU-FSCCL M M negative ++ n.d.
DLBCL DB M M/U negative + n.d.
HT M M/U negative ++ negative
SU-DHL-4 M M/U negative n.d. negative
WSU-DLCL2 U U negative - negative
MCL GRANTA-519 U U positive - positive
HBL-2 U M/U positive n.d. positive
JEKO-1 M U positive - positive
REC-1 U U positive - positive
Gene expression and induction of CD44 mRNA transcription were analyzed by qRT-PCR. Aza induction was tested after incubation of cells for 3 days with 5 μM
Aza. CD44 protein expression was analyzed by flow cytometry. MS-MLPA and MSP results: M: methylated, U: unmethylated; fold of Aza induction: + > 3 ×, ++ >
30 ×, +++ > 150 ×, - = no change; n.d.: not determined.
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Page 9 of 14Figure 5 Effect of the DNA demethylating agent Aza on CD44 expression. (A) Expression of CD44 was re-inducible by treatment of cells
with 5 μM Aza (3 days) in CD44 hypermethylated cell lines, but not in CD44 unmethylated cell lines as assessed by qRT-PCR. Expression levels of
the corresponding DMSO-controls were set to 1. (B) Aza (5 μM) treatment for 4 days induced CD44 protein expression in CD44 hypermethylated
cell lines as analyzed by flow cytometry. CD44 stained cells (filled histogram) and isotope control labeled cells (open histogram) are shown. M:
methylated; U: unmethylated; increase of CD44 positive cells: - = no change, + = > 10%, ++ = >25%.
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Page 10 of 14CD44. Promising clinical trials of anti-CD44 antibody
drug conjugates in breast cancer and head and neck
squamous cell carcinoma have already been conducted
[54]. In addition, CD44 could become a valuable new
epigenetic target in CD44 hypermethylated NHL for
treatment with DNA methyltransferase inhibitors.
Whether a combination of DNA demethylating agents
and anti-CD44 mAbs might be applicable for CD44
-
lymphoma should be an object of future studies. In
CD44
- lymphoma cell lines Aza treatment alone induced
apoptosis and a simultaneous incubation with anti-CD44
mAb showed no additive effects (data not shown).
Conclusions
Our studies on TSG methylation patterns in lymphoma
cell lines and patient samples led to the identification of
novel epigenetically silenced TSG, with CD44 being the
most interesting one. Hypermethylation of CD44 occurred
preferentially in ALCL, BL, DLBCL and FL cell lines,
whereas HL and MCL cell lines were mainly unmethylated
and tested positive for CD44 mRNA and protein. Concor-
dant with the methylation pattern observed in cell lines,
CD44 hypermethylation was identified frequently in BL
but not in MCL patients. The CD44 expression profiles
obtained from lymphoma cell lines resemble previous
reports on differential CD44 expression in diverse primary
lymphoma entities [45,55]. No regulatory mechanisms for
CD44 expression in lymphoma have been described so far.
We show here, that CD44 expression is epigenetically
regulated in lymphoma cell lines and presumably also in
primary lymphoma. CD44 hypermethylation resulted in
transcriptional silencing of the gene, which could be reac-
tivated by treatment with the DNA demethylating agent
Aza. Furthermore, ligation of cell surface CD44 with an
anti-CD44 antibody triggered apoptosis in CD44
+ lym-
phoma cell lines, whereas CD44
- cell lines with CD44
hypermethylation were resistant towards anti-CD44
induced apoptosis. These experiments support the tumor
suppressor function of CD44 in lymphoma. Therefore,
epigenetic silencing of CD44 might be advantageous dur-
ing lymphomagenesis and should be considered in further
investigations. In the future, CD44 should be evaluated as
a potential target for epigenetic therapy and as a target for
antibody-based therapies in CD44
+ lymphoma subtypes.
Additional material
Additional file 1: Methylation status and deletions of TSG in tumor
samples of 29 BL, 10 DLBCL and 11 MCL patients. MS-MLPA results
of primary lymphoma samples show the methylation status and copy
number of 24 TSG. TSG are sorted from left to right according to the
order of Figure 1. Yellow = TSG unmethylated and not deleted; green =
TSG methylated and/or deleted; del = deleted; o. del = only deleted, not
methylated; nd = not determined.
Additional file 2: CD44 variant analysis in CD44
+ lymphoma cell
lines. (A) Reverse transcriptase PCR was performed with primers (blue
arrows) flanking all variant exons (colored exons in CD44 exon structure)
of CD44 to examine expression of CD44 splice variants. (B) The agarose
gel shows that the CD44s PCR product (142 bp) was the main variant
present in the CD44
+ lymphoma cell lines and PBMC (peripheral blood
mononuclear cells). A second noticeable PCR product turned out to be
the splice variant CD44v10 after sequencing analysis. As expected, CD44
-
cell lines (NAMALWA, HT) tested negative.
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Table 2 CD44s expression in lymphoma: comparison of published data with this study
published data this study
Lymphoma subtype CD44s protein [reference] CD44 unmethylated promoter
in primary lymphomas
CD44 unmethylated
promoter in cell lines
CD44s expression in cell lines
HL pos [45] n.d. 3/7 5/7
ALCL pos [46] n.d. 2/5 3/5
BL neg [48,55] 11/29 0/7 0/7
FL
nodal FL
pos/neg [55]
neg [45]
n.d. 2/6 2/6
DLBCL pos/neg [47,55,56] 9/10 2/8 2/8
MCL pos [44] 11/11 6/7 7/7
normal lymphoid tissue pos [40,41] 3/3
Comparison of CD44s protein expression in samples of lymphoma patients as reported in the literature and CD44 methylation status and CD44s gene expression
in lymphoma cell lines and patient samples analyzed in our study. CD44 methylation status was determined by MSP (primary samples) or MS-MLPA (cell lines),
CD44 gene expression levels were analyzed by qRT-PCR. pos = most of the reported samples were CD44 positive, neg = all analyzed samples were negative for
CD44. pos/neg = CD44
+ and CD44
- samples were described, n.d. = not determined.
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Page 11 of 14Figure 6 Analysis of apoptosis after anti-CD44 ligation. (A) Apoptosis was analyzed after incubation of cells for 24 h with anti-CD44 mAb
(20 μg/ml) or isotope control antibody (20 μg/ml) by annexin-V/PI staining and measured by flow cytometry as shown for cell lines EB-1 (CD44
-)
and REC-1 (CD44
+). Data are representative of three independent experiments with similar results. (B) Mean of early apoptotic cells (annexin-V
+,
PI
-) in two CD44
+ (REC-1 and KM-H2) and two CD44
- (EB-1 and KARPAS-299) lymphoma cell lines after treatment with anti-CD44 in different
concentrations for 24 h (n = 3). The number of early apoptotic cells in the corresponding isotope controls were set to 1. Note that anti-CD44
induced apoptosis occurred only in the CD44
+ cell lines.
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